In this study, we designed a novel quinoline derivative as a potent HDAC inhibitor SDFZ‐8 and assessed its capability to enhance cancer immunotherapy, along with its potential synergistic effects with PD‐L1 blockade. Here, HDAC9 is linked to cancer.